News | National Centre for Pharmacoeconomics

Colorectal Cancer Screening programme - July 7, 2009
Health Technology Assessment (HTA) of population-based colectoral cancer screening programme in Ireland.
Rivaroxaban (Xarelto®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement - September 18, 2008
Reimbursement recommended.
Dabigatran Etexilate (Pradaxa®) for the Primary Prevention of Venous Thromboembolic Events after Total Hip/Knee Replacement - September 11, 2008
Reimbursement recommended.
Melatonin (Circadin®) - August 14, 2008
We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes.
Nilotinib (Tasigna®) CML resistant/intolerant to imatinib - February 29, 2008
The cost-effectiveness of nilotinib compared to dasatinib, in patients resistant to imatinib has not been demonstrated.
Lapatinib (Tyverb®) - January 28, 2008
Lapatinib could be considered cost-effective inIreland. However in view of the uncertainty surrounding the ICER, we (NCPE) suggest conditional reimbursement under the High Tech Drugs scheme.
Sublingual Immunotherapy (Grazax®) - September 4, 2007
The cost-effectiveness of Grazax® remains to be established and this product cannot be recommended as value for money at this point in time.
Universal Infant Hepatitis B Vaccination programme - March 8, 2007
Cost effectiveness analysis of a universal infant hepatitis B vaccination programme in Ireland
Pneumococcal conjugate vaccine - March 8, 2007
Cost effectiveness analysis of a universal infant pneumococcal conjugate vaccination programme in Ireland.
Sunitinib (Sutent®) - November 9, 2006
The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.